Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advanceme...
Biopharma Boardroom speaks with Hubert Martens, CEO of Salvia BioElectronics, about the development of the MySalvia System, an investigational implantable ...
Element Biosciences, Inc. announced the commercial launch of AVITI Dx, the company's first CE-marked in vitro diagnostic (IVD) sequencing platform under th...
SOTERIA Precision Medicine Foundation (SOTERIA), a California-based 501(c)(3) nonprofit, announces Cancer Hunt™, a nationwide precision oncology prog...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that...
Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) announced that the first patient with systemic lupus erythematosus ...
Efficacy signals suggesting improvements in pain scores were observed in Phase 2 clinical studies in postherpetic neuralgia (PHN), fibromyalgia (FM), a...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered ...
ExoCordOA, a five-year project, led by Exogenus Therapeutics and backed by Horizon Europe, brings together ten organisations spanning biotechnology, clin...
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and a pioneer in image-guided therapy, announced the launch of Philips UniGuide...
As demand for Exatecan-based antibody-drug conjugates (ADCs) grows, securing reliable manufacturing capacity and diversified supply chains has become a pri...
The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth...
FAB-KLEAR investigates lucerastat as a potential disease-modifying therapy targeting the kidney manifestations of Fabry disease. Nxera will contribute to ...
© 2026 Biopharma Boardroom. All Rights Reserved.
